COVID-19: CDC, FDA and CMS Guidance
This page includes AHA Today stories and other AHA content on coronavirus COVID-19 guidance from the CDC, FDA, and CMS.
An independent Centers for Disease Control and Prevention advisory committee recommended immediate resumption of the administration of Johnson & Johnson’s COVID-19 vaccine in the U.S.
The Food and Drug Administration revoked the emergency use authorization that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients.
The Food and Drug Administration today revoked its emergency use authorization for the COVID-19 monoclonal antibody therapy bamlanivimab when administered alone.
Drug overdose deaths in the United States rose by an estimated 29% between September 2019 and September 2020 to 90,237, according to preliminary data released by the Centers for Disease Control and Prevention.
The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices holds an emergency meeting on the Johnson & Johnson (Janssen) COVID-19 vaccine to review reports that six women aged 18-48 experienced a rare but serious condition involving blood clots and low…
The Food and Drug Administration urged health care facilities to transition away from using crisis capacity conservation strategies, such as decontamination or bioburden reduction, to extend the use of N95s and other similar disposable respirators.
The Food and Drug Administration authorized for emergency use the first prescription antibody test that allows individuals to collect a finger-stick dried blood sample at home for analysis at a Symbiotica laboratory when a health care provider deems it appropriate.
The Food and Drug Administration authorized several SARS-CoV-2 serial screening tests for asymptomatic individuals.
The Food and Drug Administration said that Moderna can add up to 50% more doses per vial of its COVID-19 vaccine. Moderna had been shipping 10-dose vials; the FDA’s change will enable shipments to contain up to 15 doses per vial.
The Federal Communications Commission adopted a report and order implementing changes to the COVID-19 Telehealth Program under the Consolidated Appropriations Act, which authorized an additional $249.95 million in funding for the program.